Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008.

Slides:



Advertisements
Similar presentations
Introduction to Existing State Disclosure Laws and Regulations Summit on Disclosure, Transparency and Aggregate Spend For Drug, Device and Biotech Companies.
Advertisements

Professional Education Support Wyeth Pharmaceuticals Melinda Somasekhar, PhD.
Drug Information for Consumers and Healthcare Professionals Food and Drug Law Institute Annual Meeting Alan Goldhammer, PhD Associate VP Regulatory Affairs.
Pharmaceutical and Medical Device Manufacturer Conduct Melissa J. Lopes, Deputy General Counsel Massachusetts Department of Public Health.
Continuing Professional Development Conflict of Interest This presentation has been developed by the COI Working Group to assist in the implementation.
Providing Control, Autonomy and Profitability for the Healthcare Provider PHYSICIANS PROVISO.
Spanish Code of Practice for the Promotion of Medicines CONFIDENTIAL "International congresses, including booth materials and panels, controls related.
Marketing to Doctors – Payments for Loyalty Julie Brill Assistant Attorney General Vermont Attorney General ’ s Office Montpelier,
Pharmaceutical Compliance Congress: “State of the States” October 27, 2008 Janice G. Cunningham Jeffrey L. Handwerker.
1 UCDHS Vendor Relations Policy Development & Implementation Teresa Porter, CHC - Chief Compliance Officer David Levine, JD - Legal Counsel Allan Siefkin,
Hospital Pharmacy Payam Parchamazad, PharmD Staff Pharmacist
Part 2  In community-based long-term care, the resident may simply need assistance with taking their medications at the right time or with preparing.
Disputing Distribution: Ethics and Pharmaceuticals in Nepal Nabin Rawal, Ian Harper and Madhusudan Subedi.
March Sliding Fee Scales, Patients Cap on Charges Eli Camhi, MSSW – Tom Hickey -
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
Introductory training Medical Technology Industry Code of Practice.
Open Payments Act AKA the ‘Sunshine Act’ Open Payments Act AKA the ‘Sunshine Act’ Public Postings of Physician Ownership, Investments, & Transfers of Value.
Implementation of Disclosure Legislation in Massachusetts National Disclosure Summit March 6, 2009 Allan Coukell, Director of Policy.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
CORPORATE COMPLIANCE Tim Timmons Vice President Compliance and Regulatory Services Health Future, LLC.
© 2008 Foley Hoag LLP. All Rights Reserved. 1 The New Massachusetts Pharmaceutical & Medical Device Marketing Regulations How to Address and Overcome Likely.
New Staff Orientation: Industry Relations Emory School of Medicine Zainab R. Wurie, JD July 15, 2014.
How to Develop Internal Monitoring Programs SEVENTH ANNUAL PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS AND BEST PRACTICES FORUM Stephen F. Mohr Global.
Todd Hamilton District Sales Manager. Innovation  On average it takes scientists, physicians, engineers, and other researchers between 10 and 15 years.
Pitfalls and Lessons Learned: Advanced Implementation Strategies for a Compliant Grant Process National CME Audioconference December 9, 2008.
“Delivering Therapeutic Agents” - Marketing and Communication Strategies of Drug Companies Safura Nantogmah.
©SHRM 2008SHRM Poll September 2, From the HR perspective, what aspect of health care policy should be the priority of the next U.S. President and.
International Congress and Convention Association International Association Overview Ross Robinson 44 th ICCA Congress & Exhibition, Monday, November 7.
+ Conflict of Interest in Physician-Industry Relationships.
Vendor Relations Policy. Why Is There A Policy? The Patient Protection and Affordable Care Act was signed into law March 23, The new law contains.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
Texas State Board of Medical Examiners Bruce A. Levy, M.D., J.D.
The Ninth Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Thomas E. Costa Bristol-Myers Squibb Company This presentation.
Codes of Conduct The International Pharmaceutical Regulatory & Compliance Congress and Best Practice Forum 6 June 2007 Heather Simmonds Director Prescription.
+ Role of Industry in Clinical Care, Research, and Education.
EFPIA and IFPMA Code Compliance Strategies Richard BERGSTRÖM Chair, EFPIA Code Steering Committee Chair, IFPMA Code Compliance Network Presentation at.
An Educational Session on HSC OP 10.27, Health Care Vendor Interactions April 20, 2009.
1 Harvard University Cambridge, MA March 29, 2007 Medical Device Congress AdvaMed’s Efforts to Promote Compliance Christopher L. White, Esq. Executive.
University medical center Introducing the UMC Web Site.
The Physician - Pharma Relationship.  Is very old and very close  But are the goals of pharmaceutical companies and medicine the same?
Session 1.01 US Healthcare Professionals Abroad – Issues and Practical Solutions Caroline West – Senior VP, Chief Compliance and Risk Officer Shire Pharmaceuticals.
BDH Discovering Tomorrow’s Healthcare Solutions Today Clinical Research Services, Inc. Basil Halliday, M.Sc. President & CEO BDH Clinical Research Services.
Lilly Answers that Matter. Preserving the Value of Industry Interactions with Health Care Professionals Jack Harris, M.D. Vice President, U.S. Medical.
California’s New Compliance Law Kelly N. Reeves
Building A Pharmaceutical Compliance Program Presentation to the Sixth Annual Congress on Health Care Compliance February 7, 2003 Janice Toran Fujisawa.
Compliance Issues in Dealing With Drug and Device Manufacturers Presentation to The Sixth Annual National Congress On Health Care Compliance Paul E. Kalb,
FDA Regulatory and Compliance Symposium Industry Collaboration & Interactions with Health Professionals: Can Conflicts of Interest be Properly Managed?
0 Due Diligence Monitoring and Auditing of Third Party Vendors October 28, 2008 Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.
Fitness Professionals, Coaches, and the Sports Medicine Team: Defining Roles.
Given the progress that continues to be made in society’s battle against disease, patients are seeking more information about medical problems and potential.
From Jan 1, no freebies for docs from pharma firms.
Private and confidential Community Pharmacy Future Four-or-more medicines support service Update on progress and next steps Approved18 th June 2012 This.
Pharmaceutical industry interactions in family medicine residencies have decreased since 2008 Steven R. Brown, MD, David V. Evans, MD, Adriane Fugh-Berman,
Healthcare Industry NAICS CODE Health Care History  Organized medicine took shape dating back to 1900s  Franklin D. Roosevelt approved public.
PHARMACEUTICAL GUIDELINES: BASIC PRINCIPLES AND STATUTES.
The IVD Australia Code of Conduct Edition 2.1
Disclosure UK Talking about Transparency.
National Pharma Audioconference Revised PhRMA Code: Key Provisions
PHARMA AUDIOCONFERENCE An Analysis of the HHS OIG Draft Compliance Program Guidance for the Pharmaceutical Industry Overview of Draft CPG Michael P.
Disclosure UK Talking about Transparency.
NATIONAL DISCLOSURE SUMMIT Friday, March 6, 2009
The Most Important Element to Assure That Your Sales and Marketing Compliance Program is Working Effectively: Monitoring and Auditing Kelly B. Freeman,
Changing the Game for Sjögren's Patients
Lilly Grant Funding Disclosure May 27, 2008
AGREEMENT FOR TRANSPARENCY The Case of Mexico
California’s “Comprehensive Compliance Program” Law
North Carolina Association Medical Staff Services MAY 15, 2008
Industry Induction Course
PHARMACOVIGILANCE SYSTEM
Presentation transcript:

Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008

The PhRMA Code has been updated as part of an ongoing effort to be responsive to the concerns of healthcare stakeholders and enhance the critical interactions between pharmaceutical research companies and physicians Approved unanimously by the PhRMA Board of Directors Code reaffirms that interactions between company representatives and healthcare professionals should be focused on informing healthcare professionals about the benefits and risks of medicines to help enhance patient care, providing scientific and educational information, and supporting medical research and education Takes effect in January 2009

New provision on training of company representatives Eliminates all “gifts” to physicians, including “reminder” items (educational items still appropriate) Prohibits sales representatives from providing restaurant meals to health care professionals Limits sales representatives to in-office or in-hospital settings with educational presentations New provision on training of company representatives New provisions on adherence to Code Annual certification of compliance by CEO and Compliance Officer Compliance Officer contact information posted on PhRMA website Third party verification encouraged

Enhances the independence of Continuing Medical Education funded by companies Sets guidelines on the use of physician prescriber data, supporting appropriate use of the data, allowing for physician opt-out, and providing a contact for physicians Requires disclosure of speaker and consulting relationships with industry for physicians on formulary and guidelines committees and requires each company to cap the amount of annual compensation an individual physician speaker can receive Requires companies to monitor health care professional speaker programs for FDA compliance

Physicians Consider Multiple Factors in Prescribing Source: KRC Research, Survey of Physicians about Pharmaceutical and Biotech Research Activities and Information, Commissioned by PhRMA, March 2008

Provide information about drug interactions Provide information about the latest drugs and treatments Answer or find out the answers to specific questions you have Provide information about assistance programs for prescription coverage Provide free drug samples Provide informational presentations for physicians and staff Provide information to give to patients Relay your reports of any side effects 95% 95% 92% 90% 89% 88% 87% 77% Source: KRC Research, Survey of Physicians about Pharmaceutical and Biotech Research Activities and Information, Commissioned by PhRMA, March 2008